Screening for chemotherapy adverse late effects

Topics in Geriatric Rehabilitation

Volumn 27, Issue 3, 2011, Pages 234-243

  Marchese, Victoria G ^a,b   Morris, G Stephen ^c   Gilchrist, Laura ^d   Ness, Kirsten K ^e,f   Wampler, Meredith ^g   Vanhoose, Lisa ^h   Galantino, Mary Lou ^i,j  

^a LEBANON VALLEY COLLEGE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ST CATHERINE UNIVERSITY   (United States)

^e Children's Hospitals Clinics of Minnesota   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g POTENTRx   (United States)

^h UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

ⁱ RICHARD STOCKTON COLLEGE OF NEW JERSEY   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

chemotherapy; outcome measures; physical therapy

Indexed keywords

ALKYLATING AGENT; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; EXEMESTANE; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; LETROZOLE; MELPHALAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PREDNISONE; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ADVERSE DRUG REACTION; ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; ARTICLE; BALANCE DISORDER; BONE DENSITY; BONE FRAGILITY; BREAST CANCER; CACHEXIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOPULMONARY FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM EXAMINATION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; ENDURANCE; ERYTHEMA; FALLING; FATIGUE; FRACTURE; FUNCTIONAL STATUS; GAIT DISORDER; HEART EJECTION FRACTION; HUMAN; IMMOBILIZATION; KYPHOSIS; LUNG EXAMINATION; MOTOR DYSFUNCTION; MUSCULOSKELETAL SYSTEM EXAMINATION; OSTEOLYSIS; OSTEOPOROSIS; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PHYSIOTHERAPY; SCAR FORMATION; SCREENING TEST; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN EXAMINATION; SKIN MANIFESTATION; TENDON REFLEX; WAIST CIRCUMFERENCE; WALKING DIFFICULTY; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 80051715755     PISSN: 08827524     EISSN: None     Source Type: Journal    
DOI: 10.1097/TGR.0b013e318219912a     Document Type: Article

References (78)

1. Balis FM, Holcenberg JS, Blaney SM. General principles of chemotherapy. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia, PA: Lippincott-Raven; 2002:237.
2. Kaste SC, Metzger ML, Minhas A, et al. Pediatric Hodgkin lymphoma survivors at negligible risk for significant bone mineral density deficits. Pediatr Blood Cancer. 2009;52(4):516-521.
3. Majhail NS, Flowers ME, Ness KK, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009;43(1):49-54.
4. Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer-a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2010;19(1):170-181.
5. Nathan PC, Ford JS, Henderson TO, et al. Health behaviors, medical care, and interventions to promote healthy living in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27(14):2363-2373.
6. Ness KK, Hudson MM, Ginsberg JP, et al. Physical performance limitations in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27(14):2382-2389.
7. Ness KK, Leisenring WM, Huang S, et al. Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2009;115(9):1984-1994.
8. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update-consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106(3):388-391. (Pubitemid 34778969)
9. National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicology Criteria (CTC) Web site. http://ctep. info.nih.gov/ protocolDevelopment/electronic-applications/ctc.htmtc-40. Published May 28, 2009. Updated 2010. Accessed October 20, 2010.
10. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Children's Oncology Group Web site. http://www.survivorshipguidelines.org/pdf/LTFUGuidelines.pdf. Published October 2008. Updated 2008. Accessed October 20, 2010.
11. Ness KK, Leisenring WM, Huang S, et al. Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2009;115(9):1984-1994.
12. Marchese VG, Chiarello LA, Lange BJ. Effects of physical therapy intervention for children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004;42(2):127-133. (Pubitemid 38173921)
13. Marchese VG, Connolly BH, Able C, et al. Relationships among severity of osteonecrosis, pain, range of motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia. Phys Ther. 2008;88(3):341-350. (Pubitemid 351323784)
14. Marchese VG, Rai SN, Carlson CA, et al. Assessing functional mobility in survivors of lower-extremity sarcoma: reliability and validity of a new assessment tool. Pediatr Blood Cancer. 2007;49(2):183-189. (Pubitemid 47041109)
15. Marchese VG, Spearing E, Callaway L, et al. Relationships among range of motion, functional mobility, and quality of life in children and adolescents after limb-sparing surgery for lower-extremity sarcoma. Pediatr Phys Ther. 2006;18(4):238-244.
16. Laack S J P A. Respiratory and cardiovascular drug actions. In: Frownfelter DL, Dean E, eds. Cardiovascular and Pulmonary Physical Therapy. 4th ed. St. Louis, MO: Mosby/Elsevier; 2006:848.
17. Huber GM. Special tests. In: Frownfelter DL, Dean E, eds. Cardiovascular and Pulmonary Physical Therapy: Evidence and Practice. 4th ed. St. Louis, MO: Mosby/Elsevier; 2006:848.
18. Scherer SA, Noteboom JT, Flynn TW. Cardiovascular assessment in the orthopaedic practice setting. J Orthop Sports Phys Ther. 2005;35(11):730-737. (Pubitemid 41654274)
19. Balady GJ, Chaitman B, Driscoll D, et al. Recommendations for cardiovascular screening, staffing, and emergency policies at health/fitness facilities. Circulation. 1998;97(22):2283-2293. (Pubitemid 28265396)
20. Thompson WR, Gordon NF, Pescatello LS, American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:380.
21. Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int. 2003;14(12):1001-1006. (Pubitemid 40824271)
22. Hijiya N, Ness KK, Ribeiro RC, Hudson MM. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer. 2009;115(1):23-35.
23. Spanik S, Spanikova B. Bone mineral density in early breast cancer patients. Bratisl Lek Listy. 2010;111(1):27-32.
24. Ghazi M, Roux C. Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer. Best Pract Res Clin Rheumatol. 2009;23(6):805-811.
25. Alibhai SM, Duong-Hua M, Cheung AM, et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19, 079 men. J Urol. 2010;184(3):918-923.
26. Shim K, MacKenzie MJ, Winquist E. Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review. Drug Saf. 2008;31(5):359-371. (Pubitemid 351565736)
27. Salaffi F, Silveri F, Stancati A, Grassi W. Development and validation of the osteoporosis prescreening risk assessment (OPERA) tool to facilitate identification of women likely to have low bone density. Clin Rheumatol. 2005;24(3):203-211. (Pubitemid 40867939)
28. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-3883. (Pubitemid 47477264)
29. Dixon D, Johnston M, McQueen M, Court-Brown C. The Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH) can measure the impairment, activity limitations and participation restriction constructs from the International Classification of Functioning, Disability and Health (ICF). BMC Musculoskelet Disord. 2008;9:114.
30. Hawker G, Melfi C, Paul J, Green R, Bombardier C. Comparison of a generic (SF-36) and a disease specific (WOMAC) (Western Ontario and McMaster Universities Osteoarthritis Index) instrument in the measurement of outcomes after knee replacement surgery. J Rheumatol. 1995;22(6):1193-1196.
31. Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol. 2005;23(24):5814-5830.
32. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556-565.
33. Irwin ML, Ainsworth BE. Physical activity interventions following cancer diagnosis: methodologic challenges to delivery and assessment. Cancer Invest. 2004;22(1):30-50. (Pubitemid 38523958)
34. O'Connell BO, Baker L, Gaskin CJ, Hawkins MT. Risk items associated with patient falls in oncology and medical settings. J Nurs Care Qual. 2007;22(2):130-137.
35. Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol. 2005;23(27):6596-6606. (Pubitemid 46190253)
36. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998-2005. (Pubitemid 41513186)
37. Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw. 2009;7(suppl 3):S1-S32; quiz S33-S35.
38. Jensen MP, Chang HY, Lai YH, Syrjala KL, Fann JR, Gralow JR. Pain in long-term breast cancer survivors: frequency, severity, and impact. Pain Med. 2010;11(7):1099-1106.
39. King NA, Caudwell P, Hopkins M, et al. Metabolic and behavioral compensatory responses to exercise interventions: barriers to weight loss. Silver Spring. 2007;15(6):1373-1383. (Pubitemid 47110899)
40. Courneya KS, Segal RJ, Mackey JR, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007;25(28):4396-4404. (Pubitemid 350013845)
41. Galantino ML, Cannon N, Hoelker T, Quinn L, Greene L. Effects on Iyengar yoga on measures of cognition, fatigue, quality of life, flexibility, and balance in breast cancer survivors: a case series. Rehabil Oncol. 2008;26(1):18-27. (Pubitemid 351696231)
42. Freeman JR, Broshek DK. Assessing cognitive dysfunction in breast cancer: what are the tools? Clin Breast Cancer. 2002;3(suppl 3):S91-99.
43. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64(2):165-176. (Pubitemid 32010334)
44. Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3(suppl 3):S84-90.
45. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20(2):485-493. (Pubitemid 34072533)
46. Hurria A, Goldfarb S, Rosen C, et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat. 2006;98(3):343-348. (Pubitemid 44195605)
47. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol. 2007;25(17):2455-2463. (Pubitemid 46999217)
48. Vardy J, Wong K, Yi QL, et al. Assessing cognitive function in cancer patients. Support Care Cancer. 2006;14(11):1111-1118. (Pubitemid 44898793)
49. Galantino ML, Brown DC, Stricker CT, Farrar JT. Development and testing of a cancer cognition questionnaire. Rehabil Oncol. 2006;24(2):15-22.
50. Stubblefield MD, Burstein HJ, Burton AW, et al. NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009;7(suppl 5):S1-S26; quiz S27-S28.
51. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR. Taxolinduced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004;109(1/2):132-142. (Pubitemid 38479779)
52. Ramchandren S, Leonard M, Mody RJ, et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst. 2009;14(3):184-189.
53. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990;66(6):1117-1123. (Pubitemid 20310648)
54. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994;35(3):304-311. (Pubitemid 24089653)
55. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903-909. (Pubitemid 44615944)
56. Markman M. Chemotherapy-induced peripheral neuropathy: underreported and underappreciated. Curr Pain Headache Rep. 2006;10(4):275-278. (Pubitemid 44122750)
57. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2006;11(2):135-141. (Pubitemid 43894080)
58. Wampler MA, Topp KS, Miaskowski C, Byl NN, Rugo HS, Hamel K. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil. 2007;88(8):1002-1008. (Pubitemid 47126397)
59. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48(2):332-338. (Pubitemid 27087598)
60. Berg KO, Maki BE, Williams JI, Holliday PJ, Wood-Dauphinee SL. Clinical and laboratory measures of postural balance in an elderly population. Arch Phys Med Rehabil. 1992;73(11):1073-1080.
61. Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986;34(2):119-126. (Pubitemid 16159911)
62. Gutiérrez-Gutiérrez G, Sereno M, Miralles A, Casado-Sáenz E, Gutiérrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol. 2010;12(2):81-91.
63. Balducci S, Iacobellis G, Parisi L, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006;20(4):216-223. (Pubitemid 43949348)
64. Nathan PA. Effects of an aerobic exercise program on median nerve conduction and symptoms associated with carpal tunnel syndrome. J Occup Environ Med. 2002;44(4):303-304.
65. Leonard DR, Farooqi MH, Myers S. Restoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy: a double-blind, randomized, placebocontrolled study with monochromatic near-infrared treatment. Diabetes Care. 2004;27(1):168-172. (Pubitemid 38196727)
66. Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp KS. Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin J Oncol Nurs. 2005;9(2):189-193.
67. Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol. 2002;14(2):212-216. (Pubitemid 34235056)
68. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008;58(4):545-570. (Pubitemid 351375051)
69. Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin North Am. 1986;70(1):187-209. (Pubitemid 16145965)
70. Sanborn RE, Sauer DA. Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. Dermatol Clin. 2008;26(1):103-119, ix. (Pubitemid 350102015)
71. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40(3):367-98; quiz 399-400. (Pubitemid 29115299)
72. Waltzer JF, Flowers FP. Bullous variant of chemotherapy-induced acral erythema. Arch Dermatol. 1993;129(1):43-45. (Pubitemid 23029665)
73. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol. 1991;24(3):457-461.
74. Demirçay Z, Gürbüz O, Alpdogan TB, et al. Chemotherapyinduced acral erythema in leukemic patients: a report of 15 cases. Int J Dermatol. 1997;36(8):593-598. (Pubitemid 27386478)
75. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004;15(6):858-862. (Pubitemid 39004339)
76. Slee PH. Images in clinical medicine. Nail changes after chemotherapy. N Engl J Med. 1997;337(3):168.
77. Smith KJ, Germain M, Skelton H. Histopathologic features seen with radiation recall or enhancement eruptions. J Cutan Med Surg. 2002;6(6):535-540. (Pubitemid 36091498)
78. Ee HL, Yosipovitch G. Photo recall phenomenon: an adverse reaction to taxanes. Dermatology. 2003;207(2):196-198. (Pubitemid 37034353)